A patient has phosphate 7.2 mg/dL, calcium 8.0 mg/dL, and PTH 250 pg/mL. What CKD-MBD pattern is suggested, and what therapy would you consider?

• A. Hyperphosphatemia with secondary hyperparathyroidism; consider phosphate binders with meals and vitamin D analogs or calcimimetics to control PTH
• B. Hypophosphatemia with adynamic bone disease; phosphate supplements
• C. Hyperphosphatemia with primary hyperparathyroidism; treat with parathyroidectomy
• D. Hypercalcemia with secondary hyperparathyroidism; restrict calcium intake

Answer: (A)

This pattern shows hyperphosphatemia with secondary hyperparathyroidism, a common CKD-MBD scenario. In CKD, phosphate tends to build up because the kidneys can’t excrete it well, and reduced vitamin D activation lowers calcium absorption. The result is high phosphate, relatively low calcium, and a compensatory rise in parathyroid hormone. That elevated PTH signal confirms secondary hyperparathyroidism rather than a primary problem with the parathyroid itself.

Therapy is aimed at lowering phosphate and controlling PTH. Use phosphate binders taken with meals to reduce intestinal phosphate absorption. To address the high PTH and improve mineral balance, consider vitamin D analogs (which help raise calcium and suppress PTH) or calcimimetics (which increase the calcium-sensing receptor sensitivity on the parathyroid to reduce PTH). In CKD patients, these approaches are often used together, with ongoing monitoring of phosphate, calcium, and PTH to avoid bringing calcium up too much or suppressing PTH too aggressively.

This isn’t describing hypophosphatemia or adynamic bone disease, and it isn’t primary hyperparathyroidism or hypercalcemia; the lab pattern fits secondary hyperparathyroidism driven by CKD-associated phosphate retention.